CAZZANIGA MARINA ELENA

Ruolo:

Ricercatore a tempo determinato

Settore scientifico disciplinare:

ONCOLOGIA MEDICA (MED/06)

Afferenza:

E-mail:

Krasniqi, E., Pizzuti, L., Barchiesi, G., Sergi, D., Carpano, S., Botti, C., et al. (2020). Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. JOURNAL OF CELLULAR PHYSIOLOGY. Dettaglio
Jacobs, S., Robidoux, A., Abraham, J., Pérez-Garcia, J., La Verde, N., Orcutt, J., et al. (2020). Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. BREAST CANCER RESEARCH, 22(1). Dettaglio
Cavaletti, G., Cornblath, D., Merkies, I., Postma, T., Rossi, E., Alberti, P., et al. (2019). Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 24(1), 111-119. Dettaglio
Cazzaniga, M., Munzone, E., Bocci, G., Afonso, N., Gomez, P., Langkjer, S., et al. (2019). Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project. ADVANCES IN THERAPY, 36(2), 381-406. Dettaglio
Cazzaniga, M., Danesi, R., Girmenia, C., Invernizzi, P., Elvevi, A., Uguccioni, M., et al. (2019). Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. BREAST CANCER RESEARCH AND TREATMENT, 176(3), 483-494. Dettaglio

Futuri studenti